论文部分内容阅读
耐甲氧西林金黄色葡萄球菌(MRSA)是一种新型金黄色葡萄球菌,它会造成严重感染性疾病。MRSA对β内酰胺类抗生素耐药性的产生及毒力的加强使得它成为了临床治疗的一大痼疾。一些虽然低效但较少产生耐药的抗生素的出现使得MRSA治疗有了新的选择。同时,研究者正在逐渐阐明MRSA基因突变和病原学特征(耐药性、毒力等)的相关性。这些成果都将为今后MRSA的临床治疗以及新药和疫苗的开发提供宝贵的理论支持与指导。
Methicillin-resistant Staphylococcus aureus (MRSA) is a new type of Staphylococcus aureus that causes serious infectious diseases. MRSA on β-lactam antibiotic resistance and increased virulence make it a major clinical treatment of chronic disease. The emergence of some though inefficient but less drug-resistant antibiotics has given MRSA a new option. Meanwhile, researchers are gradually elucidating the association between MRSA mutations and etiologic features (resistance, virulence, etc.). All of these achievements will provide valuable theoretical support and guidance for the future clinical treatment of MRSA and the development of new drugs and vaccines.